Generic Competition

Source: www.medicalnewstoday.com --- 45 days ago
As the Baby Boomer generation reaches retirement age, the number of Americans suffering from Alzheimer's disease is expected to jump from 5 million to about 14 million in 2050. ...

Source: avelient.com --- 9 days ago
In the last half of this decade, it is estimated that $100 billion worth of brand name drugs have lost (or will lose) patent exclusivity. Each year, Generic drugs take more and more of the market share from brand-name drug manufacturers. In fact, the percentage of drug prescriptions dispensed for generics increased from 47% to [...] ...

Source: au.rd.yahoo.com --- 23 days ago
Sigma Pharmaceuticals is Australia's biggest contract maker of drugs and in the past year or so it has been an indifferent performer as costs got out of control, sales growth slowed and Competition intensified.The share price dipped well under a & #36;1 to a new low around 87c in July on worries that it might suffer more pain, but speculation that retail wholesaler Metcash and foreign drugs group, Sanofi might be sniffing around saw the shares rise 55% to & #36;1.35.The shares rose 4.5c to & #36;1.395, a 3.3% increase, after being 6c higher earlier in the day.Sigma said yesterday that first-half profit rose 1% as chemist/retailers reduced the quantity of medicines they purchased ahead of changes to the Pharmaceutical Benefits Scheme.But the company's plunge into Generic drugs has also weighed on the company (it bought Arrow three years ago).Earnings in 2007 fell to just & #36;77 million after tax, the lowest for three years as the combination of rising costs, falling sales and manufacturing problems crimped profit margins.The company promised that it could do better and yesterday reported a tiny sign that it was perhaps back on track.That 1% rise in after tax earnings will help, but it was the & #36;131 million acquisition of the business of Orphan Australia which had an obvious impact on sales and profits. Without Orphan's contribution, Sigma would have had another difficult half.Sigma said in the notes to the accounts that & quot;Dur ...

Source: www.nytimes.com --- 1 day ago
The company posted higher third-quarter sales and earnings despite Generic Competition for certain medications and it raised its guidance for the year. ...

Source: www.ncbi.nlm.nih.gov --- 18 days ago
Related Articles Competition between brand-name and generics - analysis on pricing of brand-name pharmaceutical. Health Econ. 2008 Sep 24; Authors: Kong Y The objective of this paper is to provide two-stage game models explaining the 'Generic Competition Paradox' that demonstrates an increase of brand-name drug price in response to Generic entry. Under the assumption that there are two groups of consumers who are segmented by their insurance status, high insurance coverage and low insurance coverage consumers, the models indicate that the decisive factor is the market share of the high insurance coverage consumer and the size of cross-substitute factor relative to certain characteristics of market demand. The paper analyses both the case of only true Generic entry and the case of pseudo-Generic and true Generic entry. The models prove that a brand-name price will increase when both the market share of high insurance coverage consumer and the factor of cross-substitute are small. Also, the 'Generic Competition Paradox' more likely occurs in the market where less pseudo-Generic products are produced. Copyright (c) 2008 John Wiley & Sons, Ltd. PMID: 18816580 [PubMed - as supplied by publisher] ...

Source: online.wsj.com --- 2 days ago
Johnson & Johnson's profit rose 30%, as strong consumer-product and medical-device sales offset lackluster results for its pharmaceuticals unit amid Competition from Generic-drug makers. ...

Source: www.marketwatch.com --- 16 days ago
Pfizer Inc., which has faced chronic erosion of its top line due to increased Competition from Generic drugs, announced Tuesday that its research and development efforts to fill its pipeline are running ahead of schedule. ...

Source: seekingalpha.com --- 43 days ago
Ohad Hammer submits: The pharmaceutical industry is in the midst of a severe innovation crisis, where more R&D money results in less approved drugs. In parallel, sales of most traditional blockbusters are being cannibalized by Generic Competition, forcing the big pharmas to exploit new concepts and rush new drug candidates to their pipelines. Nearly half of all drugs that are expected to enter the clinic in the coming years will be aimed at the oncology market. Consequently, early stage drug development for cancer is going to be the most active area in the industry, with an abundance of investment opportunities, particularly in small and medium companies. Complete Story » ...

Source: www.techdirt.com --- 23 days ago
I recently became aware of yet another lawsuit where it looks as though a big companies with deep pockets appears to be bullying a small competitor through questionable use of intellectual property laws. The lawsuit was filed by uHaul against a small startup called HireAHelper , but also against HireAHelper's founder and his wife personally. You can see the full filing here : The main gist of the story is that Michael Glanz had signed up with a uHaul subsidiary, named eMove, offering his services as a mover. Later, Glanz ended up starting his own startup called HireAHelper, in part claiming that his experiences with eMove made him believe he could do a better job helping people find a variety of helpers (beyond just moving help apparently). Of course, here in the US, there's a long history of people breaking off from a service or company they found inadequate and creating a better competitor. That's Competition, and it drives innovation. But, to uHaul, apparently it's a threat that needs to be stamped out. The lawsuit covers a variety of different charges, almost all of which seem questionable from what's presented. The most complete charge appears to be trademark violations, but the two trademarks in question seem highly questionable by themselves: "Moving Help" and "Moving Helper" which are both Generic and descriptive -- which are two no-nos in getting a trademark. If we applied our ever popular moron in a hurry test, it seems ...

Source: www.charlotte.com --- 16 days ago
Pfizer Inc. is shifting its research focus to diseases that have high potential for treatment improvements, such as cancer and Alzheimer's disease, and where it can be a market leader. The world's biggest drugmaker also is ending new research in heart disease, including treatments for high cholesterol and hardening of the arteries, as part of a standard, periodic tweaking of its research strategy, spokeswoman Liz Power said Tuesday. Research on drugs already in late-stage human testing will continue, she said. Pfizer expects to spend between $7.2 billion and $7.5 billion on research and development this year, a huge budget for the industry. "Even though it is very large, it is finite," Power said. Like most of its competitors, Pfizer has been reorganizing and cutting costs to deal with looming Generic Competition and a lack of blockbusters in its pipeline. Power said Pfizer needs to focus research, particularly costly late-stage human testing, on areas where patient needs aren't met by existing treatments, where there's a sizable commercial market and where the company has expertise and a good chance for scientific success. The New York-based company has identified six high-priority areas for research: cancer, pain, inflammation, diabetes, Alzheimer's disease and schizophrenia. Research on drugs already in late-stage human testing will continue. Heart drugs remain a huge market given the aging population in developed countries, an ...

Source: upcoming.yahoo.com --- 15 days ago
Three perspectives on technology evolution Richard Hamilton Gibbs, Steven W. Fowkes, Tom Nufert When: Tuesday, October 14th, 6:30 - 9:00 pm Where: Fenwick & West, 801 California St., Mountain View, CA RSVP: http://www.jhtc.org Regular Admission: $10 Student Admission: $5 (ID required) Members Admission: Included (Join at http://www.jhtc.org ) Agenda 6:30 - 7:00: Networking, schmoozing and eating - Bring your job postings, business cards and resumes! 7:00 - 7:10: Welcome, committee news and other group business 7:10 - 8:30: Presentation and Discussion with our featured guests 8:30 - 9:00: Informal discussions and networking with our guests and each other A light meal and soft drinks will be provided About the Speakers Richard Hamilton Gibbs is an entrepreneur in the computer, computer peripheral, media and home entertainment markets currently researching how technological advances are affecting distribution models for music and movies and how adherence to traditional models are damaging the profitability of mainstream entertainment businesses, sabotaging revenues for artists, and alienating consumers based on Competition between proprietary and non-proprietary platforms. Steven W. Fowkes is the Director of the Cognitive Enhancement Research Institute ( http://www.ceri.com ) and a co-author of the 1993 book Smart Drugs II. Steve's expertise is the use of Generic substances (foods, dietary supplements and patent-expired pharmaceuticals) t ...

Source: www.fiercepharma.com --- 28 days ago
Here's an unlikely enemy for brand-name drugmakers: mail-order pharmacies. Patients who fill their scrips via mail order are much more likely to choose Generic drugs, according to two new studies. The exact figure was 34 percent more likely, which study sponsor Express Scripts hailed as a money-saver, but Pharma might lament as a revenue-drainer. Two pieces of good news, though. The study only covered blood pressure meds, so Generic choice might vary for other therapeutic classes. And if patients do order brand-name drugs via mail order, they're likely to be repeat customers. Compliance among mail-order patients was a full seven percentage points higher than among those who use retail pharmacies. - read the Express Scripts release Related Articles: The specter of Generic Competition grows Analysts get bullish on generics makers Drug lobby stalls pro-generics bill   Say goodbye to Big Pharma's gilded age Express Scripts mounts hostile offer for CaremarkRx  (June 2006) ...